About Us
Headquartered in the UK, we support companies in the development of market access strategies to secure timely reimbursement of innovative cancer medicines
our purpose
To provide high quality, technical input into the design of global clinical trials of cancer medicines from a commercial and health economic perspective, to address the evidence requirements of HTA agencies and payers and to secure a competitive advantage in the market.
our values
ExpertiseIndustry-leading expertise in market access strategy, health economics, patient-reported outcomes, outcomes-based payment schemes, real-world evidence and costing methods
DedicationWe offer a bespoke service, supporting assets from early development (phase I) to post-launch (phase IV)
DiscretionYou can trust our expertise and advicePatient-centric, values-driven
Oncology Access Solutions Ltd is led and founded by Dr Clare Hague – a highly experienced health economist and health services researcher with a strong industry and academic background.
With over 18 years of industry experience with large, mid-sized and start-up biotech companies in Global, Local, and Regional positions, Clare is an industry expert in the development and reimbursement of cancer medicines
Clare describes herself as a Patient-centric, values-driven Leader with a strong academic, research, consulting, and industry background. She is highly experienced at leading teams and developing strategies that secure a competitive advantage for organisations.
Clare has experience of developing market access strategies for Advanced Therapy Medicinal Products (ATMPs), PARP inhibitors, BTK inhibitors, kinase inhibitors, immune checkpoint inhibitors, monoclonal antibodies (MABs), bispecific humanized monoclonal antibodies and dual MIDH1/2 inhibitors.
Clare has experience of leading scientific advice interactions with HTA agencies, validating proposed evidence generation strategies with regulators, leading public-private (IMI) partnership initiatives, evaluating assets and companies for due diligence (acquisition) purposes, as well as advising organizations on geographic expansion opportunities for commercial growth.
Prior to working in the pharmaceutical industry, Clare worked as a Senior MRC Research Fellow at the School of Health & Related Research at the University of Sheffield.
During this time she specialised in healthcare costing methods. She was the Principal investigators of the adult ECMO [CESAR] Clinical Trial, that demonstrated the survival benefits of ECMO in patients with severe, but potentially reversible, respiratory failure.
Clare is the course leader for the masters’ degree module on Methods of Health Technology Assessment in Drug Development at the University of Lucerne. She is also a Member of Greater Manchester Central Research Ethics Committee.
LLM Healthcare Ethics & Law
2021-2023 University of Manchester
PhD Health Economics
2001-2007 University of Sheffield
BA (Hons) International Business & Spanish
1991-1995 Sheffield Hallam University
A published author with over 70 peer-reviewed publications,
Clare has presented at over 75 national and international scientific
conferences and participated in many round tables and expert panels. Her biographic details feature in Marquis’ Who’s Who in the World, Marquis’ Who’s Who in America, Marquis’ Who’s Who in
Medicine & Health Care, Marquis’ Who’s Who in Science & Engineering, Cambridge Blue Book and The Dictionary of International Biography (under maiden name of Hibbert).